GPhA IMS Report Shows Reduction in Drug Costs

Published Online: Monday, August 5, 2013
Follow Pharmacy_Times:
Generic medications brought to market as a result of patent settlements with brand name manufacturers led to a $25.5 billion reduction in drug costs over an 8-year period, according to an IMS Institute for Healthcare Informatics report conducted for the Generic Pharmaceutical Association (GPhA).

The average annual savings per year from the 33 molecule settlements analyzed amounted to $3.2 billion from 2005 to 2012, the report said. The 33 molecules were introduced in generic form an average of 81 months prior to the brand name patent expiring, with savings on each molecule ranging from $0.1 million to more than $4 billion during the 8-year period.

The federal government amassed approximately 1/3 of the total savings, which amounted to $8.3 billion over the 8-year period.

Although IMS cannot calculate the extent of future savings exactly, it predicted the remaining savings from the 33 settlements would total $61.7 billion if current trends continued through the brand name’s patent expiration.

According to GPhA President and CEO Ralph G. Neas, the report supports the controversial practice of patent settlements and also contributes to the reduction in drug expenditures.

“For years, opponents of pharmaceutical patent settlements with consideration have stated that settlements create a cost for consumers, the government, and others,” he said in the press release. “This new analysis provides the most current, complete, and transparent estimate of the impact of patent settlements on health costs, and it shows that the opposite is true. In particular, the new analysis estimates that patent settlements—including those with consideration—have led to billions in savings . . . This is critical for lawmakers to understand, because any further restrictions on settlements will put these savings at risk.”

Related Articles
For many pharmacy organizations, the Supreme Court King v. Burwell decision upholding the Affordable Care Act’s tax subsidies fended off potential confusion for patients concerning health insurance.
Today, an expert panel at the 2015 Generic Pharmaceutical Association Annual Meeting, “FDA and Industry Perspectives on Quality Culture,” convened to discuss a shared commitment with industry to the highest standards of manufacturing quality and regulatory processes.
The Generic Pharmaceutical Association today announced the election of its 2015 Executive Committee and Board of Directors.
The Generic Pharmaceutical Association and its members applaud the significant progress made by the agency during Commissioner of Food and Drugs Dr. Margaret Hamburg’s six years leading the U.S. Food and Drug Administration. Throughout her tenure, Dr. Hamburg has been a tireless advocate for patient safety and a leader in efforts to assure that FDA decisions are guided by scientific principles.
Latest Issues